Professor Risteárd Ó Laoide:

The clinical trials oversight group will be key. The report is coming out very shortly on how we can develop a national approach to this issue, which is what was done in Denmark. We have met with European colleagues on this matter. We were engaged in a process in the NCCP looking at how cancer infrastructure was being developed throughout Europe. We want Ireland to be part of the comprehensive cancer infrastructure around Europe. Our European colleagues see Ireland's size, with a population of 5 million, as a Goldilocks population that can have a single comprehensive cancer infrastructure. The governance of that needs to be part of our next cancer strategy. As part of our engagements with the Europeans on that, we had a discussion with the Danish on their clinical trials process. We can learn from them by creating a national structure for it, rather than going through each of the cancer centres, as I mentioned earlier. That is what has slowed up the process.